Abstract:Background: The overall objective of the present study is to extend our understanding of the clinical phenotype and underlying mechanism of a newly discovered cardiac arrhythmia syndrome through a multicenter study. Gain-of-function mutations in the cardiac Ca 2+ release channel (RyR2 [ryanodine receptor 2]) cause catecholaminergic polymorphic ventricular tachycardia, whereas loss-of-function RyR2 mutations are linked to a new cardiac arrhythmia disorder termed Ca 2+ -release deficiency syndrome (CRDS). Catecholaminergic polymorphic ventricular tachycardia is an inherited arrhythmia disorder characterized by stress-induced bidirectional and polymorphic ventricular tachyarrhythmias and is routinely diagnosed by using exercise stress testing. Conversely, RyR2-CRDS is characterized by ventricular arrhythmias and sudden cardiac death but a negative exercise stress testing for catecholaminergic polymorphic ventricular tachycardia. There are currently no clinical diagnostic tests for CRDS and affected patients may manifest with sudden cardiac death as their first symptom. In the absence of effective clinical diagnostic tools, in vitro functional characterization of associated RyR2 mutations provides an alternative means to identify potential cases of CRDS. Methods: We searched for patients presenting with phenotypes compatible with CRDS that have RyR2 mutations and performed in vitro functional characterization. Results: We found that 3 novel (G570D, R4147K, and A4203V) and 2 previously reported (M4109R and A4204V) RyR2 mutations associated with CRDS phenotypes markedly reduced caffeine-induced Ca 2+ release and store overload-induced Ca 2+ release. We also characterized 2 additional loss-of-function RyR2 mutations previously reported (Q3925E and L4769S) that are located in the central and channel pore-forming domains critical for Ca 2+ activation and channel gating. Q3925E was identified through postmortem genetic testing in an individual who died suddenly, while L4769S is a variant of uncertain significance reported in ClinVar, suggesting that RyR2 CRDS may be under detected. Conclusions: These findings provide further support for the existence of an emerging RyR2 loss-of-function associated arrhythmia syndrome (CRDS) and shed new insights into the disease mechanism.

New evidence supports RYR3 as a candidate gene for developmental and epileptic encephalopathy

RYR2 Mutations Are Associated With Benign Epilepsy of Childhood With Centrotemporal Spikes With or Without Arrhythmia

A De Novo Heterozygous Cardiac Ryanodine Receptor Gene (RYR2) Mutation in a Catecholaminergic Polymorphic Ventricular Tachycardia Patient

Whole-exome sequencing identifies a novel de novo mutation in DYNC1H1 in epileptic encephalopathies

One Case of Congenital Myopathy Caused by New Mutation of RYR1 Gene and Literature Review

ZFHX3 variants cause childhood partial epilepsy and infantile spasms with favourable outcomes

Clinical and Molecular Characterization of Three Novel ARHGEF9 Mutations in Patients with Developmental Delay and Epilepsy

Whole Exome Sequencing Identified a Pathogenic Mutation in RYR2 in a Chinese Family with Unexplained Sudden Death

A Chinese patient with developmental and epileptic encephalopathies (DEE) carrying a TRPM3 gene mutation: a paediatric case report

Gene Mutational Analysis in a Cohort of Chinese Children with Unexplained Epilepsy: Identification of a New KCND3 Phenotype and Novel Genes Causing Dravet Syndrome

Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature

Correlation of Phenotype–Genotype and Protein Structure in RYR1-Related Myopathy

Human RyR2 (ryanodine Receptor 2) Loss-of-Function Mutations

POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic‐atonic seizures and ataxia

Diverse Phenotypic Manifestations in a Family with a Novel RYR2 E4107A Variant

Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy

POLR3B de novo variants are a rare cause of infantile myoclonic epilepsy

De novo variants in KCNJ3 are associated with early-onset epilepsy

DLG3 variants caused X-linked epilepsy with/without neurodevelopmental disorders and the genotype-phenotype correlation

CSMD1 is a causative gene of developmental and epileptic encephalopathy and generalized epilepsies

A Heterozygous Missense Variant in the YWHAG Gene Causing Developmental and Epileptic Encephalopathy 56 in a Chinese Family.